• James George Chopas, Vice President and Chief Accounting Officer, sold 1,096 shares at approximately $30.43 each, leaving him with 48,138 shares.
• Apellis reported $709 million in U.S. net product revenues for 2024, with significant contributions from SYFOVRE® and EMPAVELI®.
• Despite a negative P/E ratio of -15.21, Apellis has a strong liquidity position with a current ratio of 4.36 and plans for future drug applications and studies.

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a biopharmaceutical company focused on developing therapies for debilitating diseases. The company is known for its innovative treatments like SYFOVRE® and EMPAVELI®. Apellis competes with other pharmaceutical companies in the market, striving to bring new solutions to patients with unmet medical needs.

On January 22, 2025, James George Chopas, the Vice President and Chief Accounting Officer of Apellis, sold 1,096 shares of the company's common stock at approximately $30.43 each. This transaction leaves him with 48,138 shares. Such insider transactions can sometimes provide insights into the company's financial health and future prospects.

Apellis has reported significant commercial growth, with U.S. net product revenues reaching $709 million in 2024. SYFOVRE® contributed $611 million, including $167 million in the fourth quarter. EMPAVELI® added $98 million, with $23 million from the fourth quarter. These figures highlight the company's strong market presence and product demand.

Looking forward, Apellis plans to submit a supplemental New Drug Application for EMPAVELI targeting C3G and primary IC-MPGN in early 2025. A U.S. launch is anticipated in the second half of 2025, pending approval. The company also aims to start Phase 3 studies of pegcetacoplan in two additional nephrology indications later in 2025.

Despite a negative price-to-earnings (P/E) ratio of -15.21, Apellis maintains a strong liquidity position with a current ratio of 4.36. The company has approximately $410 million in cash at year-end, supporting operations until profitability is achieved. The debt-to-equity ratio of 1.98 indicates significant debt usage, but the company remains well-equipped to cover short-term liabilities.